2018 Digital Innovation Award - Neuroventi Co., Ltd. Leads research on…
페이지 정보
본문
2018 Digital Innovation Award - Neuroventi Co., Ltd. Leads research on prevention and treatment of brain development disorders.
ba4f427af81b5d2795bde1cf31825a10_1674563257_6968.png
Neuroventi (CEO Shin Chan-young) is a bio venture company specializing in the prevention and development of treatments for brain development disorders such as autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD).
In addition to discovering disease targets based on basic research and research on treatment candidates, Neuroventi is concentrating on developing treatments for autism spectrum disorder by discovering targets for overcoming diseases based on big data and AI. Considering the characteristics of the new drug development field, which takes a long time to develop, it plans to provide a personalized nutrient supply platform through blood and urine analysis of patients with autism spectrum disorder so that they can be used more quickly.
Neuroventi is also making efforts to develop ADHD treatments with higher efficiency and lower side effects based on candidates that can simultaneously regulate the activity of norepinephrine, dopamine, and serotonin, which are used as existing drug targets.
In addition, it provides a systematic efficacy verification platform for natural new drug candidates through a large-scale efficacy search system, and cell and animal models for various neurological diseases to provide preclinical efficacy evaluation services for neurological diseases. In addition, it is growing into a global healthcare company that develops patient-specific medicines and customized toxicity prediction systems.